The global biologics CDMO market size is calculated at USD 25.35 billion in 2025 and is forecasted to reach around USD 92.37 billion by 2034, accelerating at a CAGR of 15.45% from 2025 to 2034. The North America biologics CDMO market size surpassed USD 7.91 billion in 2024 and is expanding at a CAGR of 15.48% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biologics CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biologics CDMO Market, by Type
8.1.1 Mammalian
8.1.1.1. Market Revenue and Forecast
8.1.2. Microbial
8.1.2.1. Market Revenue and Forecast
9.1. Biologics CDMO Market, by Molecule Type
9.1.1. Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast
9.1.2. Recombinant Proteins
9.1.2.1. Market Revenue and Forecast
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast
9.1.4. Hormones
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Biologics CDMO Market, by Product Type
10.1.1. Biologics
10.1.1.1. Market Revenue and Forecast
10.1.2. Biosimilars
10.1.2.1. Market Revenue and Forecast
10.1.3. By indication
10.1.3.1. Market Revenue and Forecast
10.1.4. Oncology
10.1.4.1. Market Revenue and Forecast
10.1.5. Auto-Immune Diseases
10.1.5.1. Market Revenue and Forecast
10.1.6. Infectious Diseases
10.1.6.1. Market Revenue and Forecast
10.1.7. Neurology
10.1.7.1. Market Revenue and Forecast
10.1.8. Others
10.1.8.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Type
11.1.2. Market Revenue and Forecast, by Molecule Type
11.1.3. Market Revenue and Forecast, by Product Type
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Type
11.1.4.2. Market Revenue and Forecast, by Molecule Type
11.1.4.3. Market Revenue and Forecast, by Product Type
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Type
11.1.5.2. Market Revenue and Forecast, by Molecule Type
11.1.5.3. Market Revenue and Forecast, by Product Type
11.2. Europe
11.2.1. Market Revenue and Forecast, by Type
11.2.2. Market Revenue and Forecast, by Molecule Type
11.2.3. Market Revenue and Forecast, by Product Type
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Type
11.2.4.2. Market Revenue and Forecast, by Molecule Type
11.2.4.3. Market Revenue and Forecast, by Product Type
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Type
11.2.5.2. Market Revenue and Forecast, by Molecule Type
11.2.5.3. Market Revenue and Forecast, by Product Type
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Type
11.2.6.2. Market Revenue and Forecast, by Molecule Type
11.2.6.3. Market Revenue and Forecast, by Product Type
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Type
11.2.7.2. Market Revenue and Forecast, by Molecule Type
11.2.7.3. Market Revenue and Forecast, by Product Type
11.3. APAC
11.3.1. Market Revenue and Forecast, by Type
11.3.2. Market Revenue and Forecast, by Molecule Type
11.3.3. Market Revenue and Forecast, by Product Type
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Type
11.3.4.2. Market Revenue and Forecast, by Molecule Type
11.3.4.3. Market Revenue and Forecast, by Product Type
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Type
11.3.5.2. Market Revenue and Forecast, by Molecule Type
11.3.5.3. Market Revenue and Forecast, by Product Type
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Type
11.3.6.2. Market Revenue and Forecast, by Molecule Type
11.3.6.3. Market Revenue and Forecast, by Product Type
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Type
11.3.7.2. Market Revenue and Forecast, by Molecule Type
11.3.7.3. Market Revenue and Forecast, by Product Type
11.4. MEA
11.4.1. Market Revenue and Forecast, by Type
11.4.2. Market Revenue and Forecast, by Molecule Type
11.4.3. Market Revenue and Forecast, by Product Type
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Type
11.4.4.2. Market Revenue and Forecast, by Molecule Type
11.4.4.3. Market Revenue and Forecast, by Product Type
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Type
11.4.5.2. Market Revenue and Forecast, by Molecule Type
11.4.5.3. Market Revenue and Forecast, by Product Type
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Type
11.4.6.2. Market Revenue and Forecast, by Molecule Type
11.4.6.3. Market Revenue and Forecast, by Product Type
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Type
11.4.7.2. Market Revenue and Forecast, by Molecule Type
11.4.7.3. Market Revenue and Forecast, by Product Type
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Type
11.5.2. Market Revenue and Forecast, by Molecule Type
11.5.3. Market Revenue and Forecast, by Product Type
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Type
11.5.4.2. Market Revenue and Forecast, by Molecule Type
11.5.4.3. Market Revenue and Forecast, by Product Type
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Type
11.5.5.2. Market Revenue and Forecast, by Molecule Type
11.5.5.3. Market Revenue and Forecast, by Product Type
12.1. 3P BIOPHARMACEUTICALS S.L.U
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Binex Co. Ltd.
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Boehringer Ingelheim International GmbH
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bora Pharmaceuticals Co. Ltd
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Catalent Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Evonik Industries AG
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. FUJIFILM Corp.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Rentschler Biopharma SE
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Samsung Electronics Co. Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample